NASDAQ · PSTX
Poseida Therapeutics, Inc.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
Loading market information…
NASDAQ · ICPT · USD
Stock price, earnings
Quote as of Nov 7, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Intercept Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.08% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Intercept Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 | May 6, 2022 | -$0.58+34.83% vs estimate | $88.58M-26.23% vs estimate |
|---|
| Q4 2021 | Mar 2, 2022 | -$1.23+2.38% vs estimate | $92.40M+1.96% vs estimate |
|---|
THE ANALYST VIEW
40 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$44.15$0.00 (0.0%)
Albireo Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.39% below the high.
$23.01+$0.02 (+0.09%)
Harpoon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.86% below the high.
$8.54$0.00 (0.0%)
Chimerix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$12.49$0.00 (0.0%)
Avid Bioservices, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.16% below the high.
$0.60-$0.10 (-14.27%)
ASLAN Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 96.48% below the high.
$15.31-$0.14 (-0.91%)
Icosavax, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
$17.16+$15.79 (+1,152.55%)
Ikena Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.29% below the high.
